Revised SPC: Alunbrig (brigatinib)

Brigatinib is now licensed as monotherapy for the treatment of adults with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer previously not treated with an ALK inhibitor.

electronic Medicines compendium